Celgene Co. (CELG) Receives New Coverage from Analysts at Standpoint Research

Celgene Co. (CELG) Receives New Coverage from Analysts at Standpoint Research


The firm set a "buy" rating and a $130.00 price target on the biopharmaceutical company's stock. Standpoint Research's price target points to a potential upside of 26.14% from the stock's previous close.



from Biotech News